海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
- 2015-11-11
Authorised
- A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate Cancer
- Metastatic Hormone-Naive Prostate Cancer (mHNPC) MedDRA version: 19.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
- 2012-09-11
Authorised
- Study to evaluate 2 types of treatment as first line treatment (masitinib + docetaxel or placebo + docetaxel ) in the treatment of patients with metastatic Castrate Resistant Prostate Cancer (mCRPC)
- metastatic Castrate Resistant Prostate Cancer (mCRPC).;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Canada, China, Czech Republic, Greece, Hong Kong, Hungary, India, Italy, Korea, Republic of, Malaysia, Mexico, Morocco, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Tunisia, Ukraine, United Kingdom, United States
- 2014-03-26
Not recruiting
- A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Czechia, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Spain, Sweden, Taiwan, United Kingdom, United States
- 2013-10-31
Authorised
- A study to assess the benefit of treatment beyond progression with enzalutamide in men who are starting treatment with docetaxel after worsening of their prostate cancer when taking enzalutamide alone
- Metastatic Castrate Resistant Prostate Cancer br>MedDRA version: 19.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Switzerland, Turkey, United Kingdom
- 2014-08-21
Not Recruiting
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL COMPARING ORTERONEL (TAK-700) PLUS PREDNISONE WITH PLACEBO PLUS PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- Australia, Belgium, Canada, Czech Republic, Estonia, Finland, France, Greece, Hungary, Italy, Netherlands, New Zealand, Poland, Singapore, Slovakia, Turkey, United States
- 2011-08-05
Not recruiting
- PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers
- Diagnostic Imaging
- Austria, United States
- 2011-01-31
Not recruiting
- Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
- Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer;Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer;Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer;Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer
- Australia, Bulgaria, Canada, Czech Republic, Czechia, France, Greece, Hungary, India, Latvia, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Slovenia, South Africa, Ukraine, United States
- 2009-06-18
Not Recruiting
- A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic - D4320C00014
- hormone-resistant prostate cancer br>MedDRA version: 6.1 Level: LLT Classification code 10062904 Term:
- Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Portugal, Sweden, United Kingdom
- 2007-07-12
Not Recruiting
- A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy
- Prostate Cancer at High Risk of Relapse After Radical Prostatectomy MedDRA version: 8 Level: PT Classification code 10060862
- Austria, Belgium, Germany, Hungary, Italy, United Kingdom
- 2005-11-04
